Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
Authors:
- Yoshinori InagakiYIYoshinori Inagaki
- Peipei SongPSPeipei Song
- Xianjun QuXQXianjun Qu
- Norihiro KokudoNKNorihiro Kokudo
- Wei TangWTWei Tang
- 1 January 2012
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 65 (1) , 23-30
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 54 references indexed in Scilit:
- MET signalling: principles and functions in development, organ regeneration and cancerNature Reviews Molecular Cell Biology, 2010
- Targeting the HGF/c-Met Axis: State of PlayMolecular Cancer Therapeutics, 2010
- Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009The Lancet Oncology, 2009
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma #Hepatology, 2009
- Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapyCancer Gene Therapy, 2005
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinomaHistopathology, 2000
- Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.Proceedings of the National Academy of Sciences, 1996
- Hepatocyte Growth Factor Enhancement of Preneoplastic Hepatic Foci Development in Rats Treated with Diethylnitrosamine and N‐Ethyl‐N‐hydroxyethylnitrosamineJapanese Journal of Cancer Research, 1995
- Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamineCarcinogenesis, 1995